Enliven Therapeutics
ELVN
ELVN
63 hedge funds and large institutions have $798M invested in Enliven Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
416.92% less ownership
Funds ownership: 512.07% → 95.15% (-417%)
Holders
63
Holding in Top 10
6
Calls
$48K
Puts
–
Top Buyers
| 1 | +$30.9M | |
| 2 | +$20.2M | |
| 3 | +$17.1M | |
| 4 |
CC
Commodore Capital
New York
|
+$12.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.32M |
Top Sellers
| 1 | -$4.72M | |
| 2 | -$2.82M | |
| 3 | -$1.92M | |
| 4 |
Millennium Management
New York
|
-$1.03M |
| 5 |
Renaissance Technologies
New York
|
-$696K |